Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101972 · ClinicalTrials.gov registry record · Phase 1
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00101972 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 53 participants.
The verdict
NCT00101972, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.
Interventions
- BIOLOGICAL monoclonal antibody RAV12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101972
The ClinicalTrials.gov registry entry for NCT00101972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody RAV12 is the first listed.
NCT00101972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101972 about?
NCT00101972 is a clinical study titled "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma". RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and bes...
What is the current status of trial NCT00101972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2004-12. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00101972?
The interventions under investigation include: monoclonal antibody RAV12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00101972?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.